share_log

Pfizer | 8-K: Poll Results of Pfizer Meeting

Pfizer | 8-K: Poll Results of Pfizer Meeting

辉瑞 | 8-K：辉瑞会议决议公告
美股SEC公告 ·  04/29 10:22
Moomoo AI 已提取核心信息
On April 25, 2024, Pfizer Inc. held its Annual Meeting of Shareholders, where several key proposals were voted upon. The nominees for Pfizer's Board of Directors were elected to serve until the next annual meeting, with votes for each nominee ranging from 3,416,127,786 to 3,641,520,694, and varying amounts of votes against and abstentions. Additionally, the selection of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2024 was ratified with a significant majority of 4,315,675,552 votes for approval. Shareholders also approved the Amended and Restated Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Company's Named Executive Officers. However, shareholder proposals to Adopt an Independent Board Chair Policy, Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures, and Publish a Report on Corporate Contributions were not approved. One proposal to Amend the Director Resignation Process was withdrawn and not presented at the meeting. The report was officially signed by Margaret M. Madden, Senior Vice President and Corporate Secretary, on April 29, 2024.
On April 25, 2024, Pfizer Inc. held its Annual Meeting of Shareholders, where several key proposals were voted upon. The nominees for Pfizer's Board of Directors were elected to serve until the next annual meeting, with votes for each nominee ranging from 3,416,127,786 to 3,641,520,694, and varying amounts of votes against and abstentions. Additionally, the selection of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2024 was ratified with a significant majority of 4,315,675,552 votes for approval. Shareholders also approved the Amended and Restated Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Company's Named Executive Officers. However, shareholder proposals to Adopt an Independent Board Chair Policy, Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures, and Publish a Report on Corporate Contributions were not approved. One proposal to Amend the Director Resignation Process was withdrawn and not presented at the meeting. The report was officially signed by Margaret M. Madden, Senior Vice President and Corporate Secretary, on April 29, 2024.
2024年4月25日，辉瑞公司举行了年度股东大会，对几项关键提案进行了表决。辉瑞董事会提名人当选的任期至下届年会，每位被提名人的选票从3,416,127,786票到3,641,520,694票不等，反对票和弃权票数目各不相同。此外，毕马威会计师事务所被选为公司2024财年独立注册会计师事务所的决定以4,315,675,552票的绝大多数获得批准。股东们还批准了经修订和重述的辉瑞公司2019年股票计划，并在咨询基础上批准了公司指定执行官的薪酬。但是，股东关于通过独立董事会主席政策、发布政治、游说、竞选支出一致性报告以及发布企业捐款报告的提案未获批准。一项修改董事辞职程序的提案被撤回，没有在会议上提出。该报告由高级副总裁兼公司秘书玛格丽特·马登于2024年4月29日正式签署。
2024年4月25日，辉瑞公司举行了年度股东大会，对几项关键提案进行了表决。辉瑞董事会提名人当选的任期至下届年会，每位被提名人的选票从3,416,127,786票到3,641,520,694票不等，反对票和弃权票数目各不相同。此外，毕马威会计师事务所被选为公司2024财年独立注册会计师事务所的决定以4,315,675,552票的绝大多数获得批准。股东们还批准了经修订和重述的辉瑞公司2019年股票计划，并在咨询基础上批准了公司指定执行官的薪酬。但是，股东关于通过独立董事会主席政策、发布政治、游说、竞选支出一致性报告以及发布企业捐款报告的提案未获批准。一项修改董事辞职程序的提案被撤回，没有在会议上提出。该报告由高级副总裁兼公司秘书玛格丽特·马登于2024年4月29日正式签署。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息